A phenocopy of sarcomeric hypertrophic cardiomyopathy: LAMP2 cardiomyopathy (Danon disease) from China

European Heart Journal

Volumn 33, Issue 5, 2012, Pages 570-572

  Maron, Barry J ^a  

^a MINNEAPOLIS HEART INSTITUTE FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LYSOSOME ASSOCIATED MEMBRANE PROTEIN 2;

CAUSAL ATTRIBUTION; CHINA; DANON DISEASE; GENETIC DISORDER; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE BIOPSY; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; PHENOTYPE; PRIORITY JOURNAL; REVIEW;

FRAMESHIFT MUTATION; GLYCOGEN STORAGE DISEASE TYPE IIB; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; LYSOSOME-ASSOCIATED MEMBRANE GLYCOPROTEINS; MALE; MYOCARDIUM;

EID: 84857970783     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehr438     Document Type: Review

References (10)

1. Seidman CE, Seidman JG. Identifying sarcomere gene mutations in hypertrophic cardiomyopathy: a personal history. Circ Res 2011;108:743-750.
2. Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE, Shah PM, Spencer WH, Spirito P, ten Cate FJ, Wigle ED. American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy. A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines Committee to Develop an Expert Consensus Document on Hypertrophic Cardiomyopathy. J Am Coll Cardiol 2003;42:1687-1713.
3. Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA 2002;287: 1308-1320. (Pubitemid 34250486)
4. Arad M, Penas-Lado M, Monserrat L, Maron BJ, Sherrid M, Ho CY, Barr S, Karim A, Olson TM, Kamisago M, Seidman JG, Seidman CE. Gene mutations in apical hypertrophic cardiomyopathy. Circulation 2005;112:2805-2811. (Pubitemid 41641675)
5. Maron BJ, Roberts WC, Arad M, Haas TS, Spirito P, Wright GB, Almquist AK, Baffa JM, Saul JP, Ho CY, Seidman J, Seidman CE. Clinical outcome and phenotypic expression in LAMP2 cardiomyopathy. JAMA 2009;301:1253-1259.
6. Maron BJ, Roberts WC, Ho CY, Kitner C, Haas TS, Wright GB, Moazami N, Feldman DS. Profound left ventricular remodeling associated with LAMP2 cardiomyopathy. Am J Cardiol 2010;106:1194-1196.
7. Boucek D, Jirikowic J, Taylor M. Natural history of Danon disease. Genet Med 2011;13:563-568.
8. Charron P, Villard E, Sébillon P, Laforêt P, Maisonobe T, Duboscq-Bidot L, Romero N, Drouin-Garraud V, Frébourg T, Richard P, Eymard B, Komajda M. Danon's disease as a cause of hypertrophic cardiomyopathy: a systematic survey. Heart 2004;90:842-846. (Pubitemid 39005922)
9. Sugie K, Yamamoto A, Murayama K, Oh SJ, Takahashi M, Mora M, Riggs JE, Colomer J, Iturriaga C, Meloni A, Lamperti C, Saitoh S, Byrne E, DiMauro S, Nonaka I, Hirano M, Nishino I. Clinicopathological features of genetically confirmed Danon disease. Neurology 2002;58:1773-1778. (Pubitemid 34663577)
10. Cheng Z, Cui Q, Tian Z, Xie H, Chen L, Fang L, Zhu K, Fang Q. Danon disease as a cause of concentric left ventricular hypertrophy in patients who underwent endomyocardial biopsy. Eur Heart J 2012;33:649-656.